Biogen Idec Inc. company was founded in 1985 and is based in Cambridge, Massachusetts. Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company’s products address diseases such as multiple sclerosis, non-Hodgkin’s lymphoma (NHL), rheumatoid arthritis (RA), crohn’s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Genencor manufactures genetically modified enzymes for the industrial, agricultural, and consumer products markets. Using its biotechnology know-how, the company discovers useful enzymes (naturally occurring protein catalysts) and develops them for mass production; the enzymes are used in myriad ways, including as additives in animal feed and detergents, as a method of converting starch into ethanol, and in the production of textiles and paper. Genencor International is a division of food ingredient company Danisco.

Guerbet Group is one of Europe's leading makers of contrast agents used in medical imaging. Most of the company's products, such as Xenetix, Hexabrix, and Dotarem, are substances that are injected into the body to make internal organs visible during X-ray and magnetic resonance imaging (MRI) examinations. Subsidiary Simafex manufactures specialty chemicals for use in pharmaceuticals. Guerbet has operations in some 15 countries and is targeting growth in the US. Marcel Guerbet, grandfather of chairman Michel Guerbet, developed the first iodinated contrast agent around the turn of the century; his descendants control the company.

Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California. Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006.

Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California. Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin in Phase 3 trial program for the treatment of obesity; APD791, an anti-thrombotic drug candidate, which has completed Phase 1a and Phase 1b clinical trials; and APD125 that is in Phase 2b clinical trial for the treatment of insomnia. The company's clinical development programs also include APD597, an oral GPR119 agonist that is in Phase 1 clinical trial for the treatment of type 2 diabetes; APD916 drug candidate, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension. Its drug candidates use GPCR-focused drug discovery and development approach, as well as technologies, including constitutively activated receptor technology and melanophore technology.

Hollis-Eden Pharmaceuticals, Inc. company was founded in 1992 and is headquartered in San Diego, California. Hollis-Eden Pharmaceuticals Inc., a development stage pharmaceutical company, engages in the discovery and development of products for the treatment of diseases and disorders, in which the body is unable to mount immune or metabolic response due to disease or the process of aging. The company focuses on developing a series of adrenal steroid hormones and hormone analogs that are derived from its Hormonal Signaling Technology Platform. It develops two clinical drug development candidates, TRIOLEX (HE3286), which is in initial clinical trials for the treatment of type 2 diabetes, ulcerative colitis, and rheumatoid arthritis; and APOPTONE (HE3235) that is in a clinical trial for late-stage prostate cancer. The company is also exploring APOPTONE for other cancers, such as breast cancer. In addition, Hollis-Eden Pharmaceuticals has a research program that is generating clinical leads for evaluation in preclinical models of various diseases, including metabolic and autoimmune conditions, as well as inflammatory diseases of the lung, bone metabolism, and regenerative medicine.

Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France. Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications in France. Its Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides, and other large and small molecules injected subcutaneously. The company's Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement. Its products based on Medusa technology include Interferon-AlphaXL, an interferon-alpha 2b for the treatment of hepatitis C virus and various oncology applications; FT-105 basal insulin, a long-acting formulation of recombinant human insulin to insulin-dependent patients; and interleukin-2 for the treatment of renal cancer. The company's products based on Micropump technology comprise Coreg CR, an extended release formulation of carvedilol phosphate for use in the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction, and hypertension; and Asacard162.5mg, a controlled release formulation of aspirin, which provide therapy for cardiovascular treatment. It has strategic alliances with GlaxoSmithKline, Merck Serono, Wyeth Pharmaceuticals, Pfizer, Corning S.A., Servier, and Corning Incorporated.

Actavis is Icelandic for generic. Iceland-based Actavis Group is one of the world's largest generic pharmaceuticals producers. Actavis company has about 350 drugs in its development pipeline, and nearly 1,000 products on the market across a variety of therapeutic classes (among them cardiovascular, gastrointestinal, and oncology). It also manufactures generic hospital products, including antibiotics, anesthetics, and painkillers. Actavis makes drugs in pill, injectable, suppository, and other forms. Subsidiary Medis distributes its drugs worldwide. Actavis, which was founded in 1956, is controlled by chairman Thor Bjorgolfsson through his investment vehicle Novator. At the company's helm is CEO Sigurdur Oli Olafsson.

Futura Medical plc company, which develops pharmaceutical and other medical products for sexual dysfunctions in both men and women, uses the DermaSys technology in its MED2002 non-prescription topical gel being developed with GlaxoSmithKline as an erectile dysfunction product. Futura is exploring other applications for DermaSys as MED2002 continues clinical trials. Other products include CSD500, a device to reduce condom slippage, and FLD 500, the company's Female Lubrication Device that is globally marketed and distributed by SSL International.

MerseyBIO is an incubator for young biotechnology businesses. Backed by the University of Liverpool and National Health Service, the company provides office and laboratory space, as well as business, investment, and technical support services to biotechnology entrepreneurs. MerseyBIO, which can incubate up to 15 biotechnology businesses, also networks its member biotechnology companies with other biotechnology firms and resources around the world. Provexis plc became the first flotation of a MerseyBIO-based company.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.